Ironwood Pharmaceuticals price to book ratio IRWD

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 2.4×; Aug 2023
10-year median: 3.4×
10-year range: 2.2× to 98.2×
Peer median: 2.4×

Ironwood Pharmaceuticals' price to book ratio is not a meaningful number today: shareholders' equity was zero, negative or not reported, so price to book does not exist.

It was last meaningful in Aug 2023, at 2.4×.

On the days it had one over the last ten years, its median was 3.4×, from 2.2× in Jul 2023 to 98.2× in Jun 2017.

Price to book ratio over time

median 3.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	2.4×	2.2×	3.3×
2022	3.2×	2.8×	3.6×
2021	3.3×	3.1×	29.1×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	88.3×	34.4×	98.2×
2016	37.6×	11.9×	41.2×
2015	16.5×	10.5×	29.9×
2014	19.3×	8.6×	47.7×
2013	17.0×	7.3×	29.0×
2012	6.5×	6.2×	13.7×
2011	10.7×	8.3×	10.9×

Against its peers

Companies in Drug Manufacturers - General nearest Ironwood Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	4.1×
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
ARVNArvinas	0.8×
COLLCollegium Pharmaceutical	2.4×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
PCRXPacira BioSciences	2.2×
ANABAnaptysbio	138×
Peer median	2.4×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Ironwood Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.